Area of research
Oncology · Hematology
Research interest
Research interests include CAR-T cell therapy research, Acute Lymphoblastic Leukemia research, Acute Myeloid Leukemia Research, and Hematopoietic Stem Cell Transplantation.
Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL
Outcomes of brexucabtagene autoleucel in patients with relapsed/refractory acute lymphoblastic leukemia with CNS involvement
CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL
Inhibition of Ephrin B2 Reverse Signaling Abolishes Multiple Myeloma Pathogenesis
Brexucabtagene Autoleucel in Adults with Relapsed/Refractory B-Cell ALL: Outcomes and Novel Insights from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)
Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy
Neuropilin 1 regulates bone marrow vascular regeneration and hematopoietic reconstitution
Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma
Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia: A single institution experience
Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with Diffuse Large B-Cell Lymphoma (DLBCL): Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry
Distinct Bone Marrow Sources of Pleiotrophin Control Hematopoietic Stem Cell Maintenance and Regeneration
Dickkopf-1 promotes hematopoietic regeneration via direct and niche-mediated mechanisms
Emerging strategies for high-risk and relapsed/refractory acute myeloid leukemia: Novel agents and approaches currently in clinical trials